Helen Reeves

Helen Reeves Graduated from Nottingham Medical school in 1990 before moving to Newcastle-upon-Tyne in 1991. She completed her basic training in Hepatology in parallel with basic science research, being awarded a PhD studying signaling pathways central to liver fibrogenesis in 2001. She subsequently completed 3 years training as a postdoctoral scientists with Professor Scott Friedman at Mount Sinai Medical School in New York, focusing largely on molecular pathogenesis of cancers, before returning to Newcastle as a Senior Clinician Scientist in 2004. She is presently the clinical hepatology lead for care of patients with HCC in Northern England, while academically she heads a team of 10 basic scientists and students in the Northern Institute for Cancer Research at Newcastle University.

1books edited

Latest work with IntechOpen by Helen Reeves

The prognosis for individuals with liver cancer is frequently poor. Cancers include those which have metastasized to the liver from elsewhere, reflecting advanced stage disease where cure is rarely possible. Similarly, primary liver cancer frequently complicates chronic liver disease, which further limits therapeutic options. Despite these dismal facts, there are signs that change is imminent. Not only have imaging modalities and surgical techniques improved, but preventive strategies and medical therapies show promise. The topic of liver tumors is comprehensively reviewed in this book, with a focus on recent developments relevant to both researchers and clinicians.

Go to the book